Clinical trial
Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant…
NCT00103467 · VaxGen, Industry · Completed
Key facts
| NCT number | NCT00103467 |
|---|---|
| Title | Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine |
| Official title | A Phase 1 Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine |
| Lead sponsor | VaxGen, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Prevention of Anthrax Infection |
| Intervention type | Biological |
| Interventions | rPA102 Vaccine |
| Enrollment | 100 |
| Start date | Jun 1, 2003 |
| First posted | Feb 9, 2005 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: